Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin and Nivolumab in Early Stage Classic Hodgkin Lymphoma
NCT05675410Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2023
- Primary completion
- Apr 2031
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of brentuximab vedotin and nivolumab in classic Hodgkin lymphoma (cHL) (8 arms), sponsored by National Cancer Institute. Primary endpoints: Progression-free survival in rapid early responder patients up to 3 years and Progression-free survival in slow-early responder patients up to 3 years. Started May 2023; status: recruiting.
02
Drugs
brentuximab vedotinnivolumab
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05675410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675410.